Passage Bio, Inc.
Passage Bio, Inc. (PASG) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PASG · as of Sep 30, 2025
Ownership Breakdown
30
Institutional Holders
▼ 9 vs Q2
$13.25M
Total Inst. Value
▼ $19.76M vs Q2
3.21M
Shares Outstanding
freeFloat 89.99%
1.65M
13F Shares Held
▼ 33.40M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PASG largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 623.7K | 19.68% | 19.68% | $5.01B | Nov 13, 2025 | NEW |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 305.0K | 9.62% | 9.62% | $2.45B | Nov 14, 2025 | NEW |
ERSTE ASSET MANAGEMENT GMBH biological products, (no diagnostic substances) | 122.8K | 3.87% | 3.87% | $999.46M | Nov 12, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 117.0K | 3.69% | 3.69% | $937.41M | Nov 7, 2025 | NEW |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 100.8K | 3.18% | 3.18% | $809.34M | Nov 13, 2025 | NEW |
NEW LEAF VENTURE PARTNERS, L.L.C. biological products, (no diagnostic substances) | 87.4K | 2.76% | 2.76% | $702.03M | Nov 14, 2025 | ▼ 2.41M |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 75.0K | 2.37% | 2.37% | $602.25M | Nov 14, 2025 | NEW |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 59.0K | 1.86% | 1.86% | $474.14M | Nov 14, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 29.7K | 93.88% | 93.88% | $238.88M | Nov 12, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 27.3K | 86.10% | 86.10% | $218.58M | Nov 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+8.9K shares27
New Positions
first time holders3
Decreased
−2.41M shares19
Sold Out
fully exitedNet shares change (top 50)
2.40M
+8.9K / −2.41M
Net new holders
+6
27 new / 19 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PASG insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sondhi Dolan director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
Porter Derrell director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
Kassberg Thomas Richard director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
Kapadia Sandip director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
GOWEN MAXINE director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
Countouriotis Athena director | May 19, 2026 | Award | 10,539 | $5.08 | $53.5K | 10.5K | Form 4 ↗ |
Borthwick Kathleen CFO | Mar 16, 2026 | Award | 15,610 | $7.64 | $119.3K | 15.6K | Form 4 ↗ |
Chou William PRESIDENT AND CEO | Mar 16, 2026 | Award | 58,000 | $7.64 | $443.1K | 58.0K | Form 4 ↗ |
Chou William PRESIDENT AND CEO | Jan 8, 2026 | Sale | 4,076 | $18.44 | $75.2K | 6.5K | Form 4 ↗ |
Borthwick Kathleen CFO | Jan 8, 2026 | Sale | 2,062 | $18.44 | $38.0K | 5.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Passage Bio, Inc. (PASG) is primarily owned by institutional investors, who hold approximately 51.4% of total shares outstanding. Company insiders own approximately 10.01%, while retail and public investors account for the remaining 38.59%.
The largest institutional shareholder of Passage Bio, Inc. is LYNX1 CAPITAL MANAGEMENT LP, holding approximately 623,704 shares — equal to 19.68% of outstanding shares — as of September 30, 2025.
A total of 30 institutional investors currently hold PASG stock, with a combined institutional value of approximately $13,248,773 as of the most recent 13F filing period.
Frequently asked questions
PASG ownershipPassage Bio, Inc. (PASG) is primarily owned by institutional investors, who hold approximately 51.4% of shares. The largest shareholder is LYNX1 CAPITAL MANAGEMENT LP with a 19.68% stake. Company insiders hold 10.01%. Data sourced from SEC Form 13F as of September 30, 2025.